Avisi Technologies Inc. products

VisiPlate is a next-generation aqueous shunt that aims to treat glaucoma. VisiPlate is 20x thinner than a human hair. VisiPlate® is an investigational device not available for use or sale in the United States. This website previews our anticipated benefits to glaucoma patients after completion of research and development.

Glaucoma is the second leading cause of blindness in the world and currently has no cure. In glaucoma patients, excess fluid within the eye builds up and puts pressure on the optic nerve. This pressure leads to irreversible vision loss. Glaucoma is a group of diseases, the two most common being primary open-angle glaucoma and angle-closure glaucoma. Primary open-angle glaucoma (POAG) is the most common type of glaucoma. There are typically no early warning signs or symptoms. In POAG, the drainage system (trabecular meshwork) within the front of the eye is clogged. Fluid is unable to cycle and drain as normal, thus leading to increased pressure within the eye. If POAG is not diagnosed and treated, it can cause gradual blindness over many years. POAG usually responds well to medication, especially if diagnosed and treated early.